title: Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.
authors.affiliation: Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Kumar
authors.forename: L
authors.initials: L
authors.lastname: Armstrong
authors.forename: Z
authors.initials: Z
authors.lastname: Yin
authors.forename: M
authors.initials: M
authors.lastname: Malkowski
authors.forename: E
authors.initials: E
authors.lastname: Maxwell
authors.forename: H
authors.initials: H
authors.lastname: Ling
authors.forename: B
authors.initials: B
authors.lastname: Yaremko
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Varner
authors.forename: E M
authors.initials: EM
authors.lastname: Smith
authors.forename: B
authors.initials: B
authors.lastname: Neustadt
authors.forename: T
authors.initials: T
authors.lastname: Nechuta
mesh_terms: D000818:Animals; D006801:Humans; D016023:Integrins / Q000378:metabolism / Q000502:physiology*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*
chemical_list: D016023:Integrins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5